What are the management steps for a patient with a Brivataracetam (Brivaracetam) overdose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Brivaracetam Overdose

There is no specific antidote for brivaracetam overdose; management focuses on supportive care with airway protection, adequate oxygenation and ventilation, and continuous cardiac monitoring. 1

Initial Stabilization and Monitoring

Immediately secure the airway and ensure adequate oxygenation and ventilation, as brivaracetam overdose can cause respiratory depression and altered mental status. 1 Endotracheal intubation should be performed if respiratory depression is present or if airway protective reflexes are compromised. 2

Establish continuous cardiac monitoring to detect bradycardia, which has been reported in brivaracetam overdose cases. 1 Monitor cardiac rate, rhythm, and vital signs throughout the observation period. 1

Obtain IV access immediately and perform bedside glucose testing to exclude hypoglycemia as a contributing factor to altered mental status. 3

Expected Clinical Presentation

The adverse reactions associated with brivaracetam overdose include:

  • Somnolence and dizziness (most common) 1
  • Vertigo and balance disorder 1
  • Fatigue and nausea 1
  • Diplopia and anxiety 1
  • Bradycardia 1

A patient who ingested 1400 mg (14 times the highest recommended single dose) experienced somnolence and dizziness as the primary manifestations. 1 The adverse reactions in overdose are generally consistent with the known side effect profile of therapeutic brivaracetam use. 1

Specific Treatment Considerations

Atropine 0.5-1.0 mg IV every 3-5 minutes should be administered for symptomatic bradycardia causing hemodynamic instability. 2 This is the only specific pharmacologic intervention that may be required beyond supportive care.

Do not administer flumazenil or naloxone, as these agents have no role in brivaracetam toxicity and will not reverse the effects. 2, 4 Brivaracetam is not a benzodiazepine or opioid despite causing CNS depression. 2

Hemodialysis is not expected to enhance brivaracetam clearance because less than 10% of the drug is excreted unchanged in urine. 1 Brivaracetam is primarily metabolized via hydrolysis and CYP2C8-mediated hydroxylation, with over 95% of the dose (including metabolites) excreted renally within 72 hours. 5

Ongoing Management

Contact a certified poison control center for updated management guidance specific to the clinical scenario. 1

Continue monitoring until all symptoms completely resolve and vital signs normalize for at least 24 hours. 3 Given brivaracetam's half-life of approximately 8 hours, patients may require extended observation. 5

Psychiatric evaluation is mandatory before discharge for intentional ingestions to assess suicide risk and ensure appropriate follow-up. 3

Critical Pitfalls to Avoid

Do not assume specific antidotes will help: Unlike some other drug overdoses, there is no reversal agent for brivaracetam toxicity. 1

Do not overlook co-ingestions: Always evaluate for other substances that may require specific antidotes or alter the clinical presentation. 2 Brivaracetam is commonly used with other antiepileptic drugs, and polypharmacy overdoses may complicate management. 6

Do not prematurely discontinue monitoring: The duration of symptoms may extend beyond initial presentation, particularly with large ingestions. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Tetrahydrozoline Overdose Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Accidental Sertraline Overdose

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Brivaracetam (UCB 34714).

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.